The trademark application AIMOVIG DIRECT was filed by Amgen Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on May 12, 2020, and it was registered by office on August 19, 2020 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and professional address of the trademark registration was recorded on November 5, 2023.
Goods And Services
The mark was filed in class 35 with Medical cost reimbursement assistance services, namely, providing assistance to patients relating to the reimbursement of medical expenses in the nature of business administration of patient reimbursement programs.
The mark was filed in class 44 with Providing medical services and information to Health Care professionals and patients.